We are live on ! Find out more
CDAK

Codiak BioSciences, Inc. Common Stock
CDAK

Delisted

CDAK was delisted on the 4th of April, 2023.

Back to rankings

40 hedge funds and large institutions have $5.76M invested in Codiak BioSciences, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% less funds holding

Funds holding: 48 → 40 (-8)

17% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 12

54% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 13

58% less capital invested

Capital invested by funds: $13.6M → $5.76M (-$7.85M)

Holders
40
Holders Change
-8
Holders Change %
-16.67%
% of All Funds
0.64%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
10
Reduced
12
Closed
13
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
-$8K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$153K
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$82.4K
3
VF
Virtu Financial
New York
+$34.5K
4
FA
Forefront Analytics
Pennsylvania
+$28.6K
5
Bank of America
Bank of America
North Carolina
+$22.4K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$782K
2
APF
Alaska Permanent Fund
Alaska
-$767K
3
BC
Boxer Capital
California
-$382K
4
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$176K
5
BlackRock
BlackRock
New York
-$82.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
HighTower Advisors
26
HighTower Advisors
Illinois
$8K – – –
Morgan Stanley
27
Morgan Stanley
New York
$6.78K -$10.6K -16,048 -48%
Two Sigma Advisers
28
Two Sigma Advisers
New York
$5.41K +$8.95K +13,600 New
BRWA
29
B. Riley Wealth Advisors
Florida
$3.98K -$2.75K -4,172 -29%
BAM
30
Belpointe Asset Management
Nevada
$996 +$1.65K +2,506 New
Citigroup
31
Citigroup
New York
$179 +$14 +22 +5%
US Bancorp
32
US Bancorp
Minnesota
$119 – – –
Wells Fargo
33
Wells Fargo
California
$65 -$188 -285 -64%
UBS Group
34
UBS Group
Switzerland
$36 -$105 -159 -64%
SIC
35
Salem Investment Counselors
North Carolina
$20 – – –
Group One Trading
36
Group One Trading
Illinois
$9 – – –
IRC
37
Investors Research Corp
Georgia
$9 – – –
AC
38
Armistice Capital
New York
– -$782K -1,000,000 Closed
APF
39
Alaska Permanent Fund
Alaska
– -$767K -980,194 Closed
BC
40
Boxer Capital
California
– -$382K -488,157 Closed
TMC
41
Trellus Management Company
Florida
– -$51K -64,582 Closed
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
– -$30K -38,209 Closed
E
43
Ergoteles
New York
– -$30K -38,019 Closed
Bank of New York Mellon
44
Bank of New York Mellon
New York
– -$14K -18,046 Closed
Man Group
45
Man Group
United Kingdom
– -$12K -15,198 Closed
Qube Research & Technologies (QRT)
46
Qube Research & Technologies (QRT)
United Kingdom
– -$8K -10,421 Closed
WAM
47
Warberg Asset Management
Illinois
– -$8K -10,000 Closed
DA
48
Denali Advisors
California
– -$7K -9,100 Closed
JP Morgan Chase
49
JP Morgan Chase
New York
– -$855 -1,299 -94%
Simplex Trading
50
Simplex Trading
Illinois
– +$100 +152 New
1
2
3

CDAK Hedge Fund Activity: Q4 2022 in Review

40 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Codiak BioSciences, Inc. Common Stock (CDAK) for Q4 2022, worth a combined $5.76M — down 58% from $13.6M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CDAK and 6 opened new positions — a net loss of 7 holders — while 12 trimmed existing stakes and 10 added.

The largest buyer was Renaissance Technologies, adding an estimated $153K. The largest seller was Armistice Capital, exiting entirely with an estimated $782K sold.

  • 40 institutional investors held Codiak BioSciences, Inc. Common Stock (CDAK) as of Q4 2022, down from 48 in Q3 2022.
  • Funds reported $5.76M of Codiak BioSciences, Inc. Common Stock stock for Q4 2022, down 58% quarter-over-quarter.
  • 6 funds opened new Codiak BioSciences, Inc. Common Stock positions in Q4 2022 and 13 closed out, a net change of -7 holders.
  • The largest Codiak BioSciences, Inc. Common Stock buyer in Q4 2022 was Renaissance Technologies, an estimated $153K added.
  • The largest Codiak BioSciences, Inc. Common Stock seller in Q4 2022 was Armistice Capital, an estimated $782K sold.

Based on aggregated 13F filings for Q4 2022.